You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 27, 2024

Details for Patent: 8,648,037


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 8,648,037 protect, and when does it expire?

Patent 8,648,037 protects MAVYRET and is included in two NDAs.

Protection for MAVYRET has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has eighty-one patent family members in forty-one countries.

Summary for Patent: 8,648,037
Title:Macrocyclic proline derived HCV serine protease inhibitors
Abstract: The present invention discloses compounds of Formula I or pharmaceutically acceptable salts, esters, or prodrugs thereof: ##STR00001## which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
Inventor(s): Or; Yat Sun (Watertown, MA), Ma; Jun (Belmont, MA), Wang; Guoqiang (Belmont, MA), Long; Jiang (Wayland, MA), Wang; Bin (Brookline, MA)
Assignee: Enanta Pharmaceuticals, Inc. (Watertown, MA)
Application Number:13/237,120
Patent Claim Types:
see list of patent claims
Use; Composition; Compound;
Patent landscape, scope, and claims:

United States Patent 8,648,037: A Detailed Analysis

Overview of the Patent

The United States Patent 8,648,037, titled "Macrocyclic proline derived HCV serine protease inhibitors," was issued on February 11, 2014. This patent is assigned to Enanta Pharmaceuticals, Inc. and focuses on compounds effective against the Hepatitis C virus (HCV)[2].

Inventors and Assignee

The inventors listed for this patent include Or Yat Sun, Ma Jun, Wang Guoqiang, Long Jiang, and Wang Bin. The assignee is Enanta Pharmaceuticals, Inc., a company known for its work in developing treatments for various diseases, including HCV[2].

Claims and Scope

Compound Description

The patent describes compounds of Formula I, which are macrocyclic proline-derived inhibitors of the HCV serine protease. These compounds are designed to inhibit the replication of the HCV virus, a critical step in treating HCV infections[2].

Pharmaceutical Compositions

The patent includes claims for pharmaceutical compositions comprising these compounds, either as free bases or as pharmaceutically acceptable salts, esters, or prodrugs. These compositions can be formulated in various ways, including amorphous solid dispersions, to enhance bioavailability and stability[2].

Methods of Use

The patent also covers methods of using these compounds to treat HCV infection. This includes administering the compounds alone or in combination with other anti-HCV agents to patients suffering from HCV[2].

Patent Expiration Dates

The patent is set to expire on January 19, 2032. This expiration date is crucial for understanding the timeline during which Enanta Pharmaceuticals, Inc. holds exclusive rights to these compounds and their use in treating HCV[2].

Technical Details

Chemical Structure

The compounds described in the patent have a specific macrocyclic structure derived from proline, which is essential for their inhibitory activity against the HCV serine protease. The detailed chemical structures and synthesis methods are outlined in the patent to ensure reproducibility and clarity[2].

Pharmacological Activity

These compounds have been shown to inhibit the HCV serine protease effectively, which is a key enzyme in the HCV replication cycle. The inhibition of this enzyme disrupts the virus's ability to replicate, thereby treating the infection[2].

Patent Landscape

Related Patents

The patent landscape for HCV treatments is complex and involves multiple patents from various companies. For example, AbbVie Inc. holds several patents related to anti-viral compounds effective against HCV, with expiration dates ranging from 2030 to 2036[2].

Competitive Analysis

Enanta Pharmaceuticals, Inc.'s patent 8,648,037 is part of a broader landscape of HCV treatment patents. The company's focus on macrocyclic proline-derived inhibitors differentiates its approach from other treatments, such as those developed by AbbVie Inc. This differentiation is crucial for market positioning and intellectual property protection[2].

Claim Coverage and Scope Concepts

Claim Analysis

The claims in this patent are detailed and specific, covering the compounds, their pharmaceutical compositions, and methods of use. Analyzing these claims using tools like Claim Coverage Matrix and Claim Charts can help in understanding the breadth and depth of the patent protection. This analysis is essential for identifying gaps or opportunities in the patent landscape[3].

Scope Concepts

The scope concepts related to this patent include the inhibition of HCV serine protease, the use of macrocyclic proline-derived compounds, and the formulation of these compounds into pharmaceutical compositions. These concepts are critical for categorizing and analyzing the patent claims in the context of the broader HCV treatment landscape[3].

Impact on HCV Treatment

Clinical Significance

The compounds described in this patent have significant clinical implications for the treatment of HCV. By inhibiting the HCV serine protease, these compounds offer a targeted therapeutic approach that can be used alone or in combination with other treatments to enhance efficacy[2].

Market Impact

The patent's expiration in 2032 will have implications for the market, as it could open up opportunities for generic versions of these compounds. However, as of now, there are no generic versions available, and Enanta Pharmaceuticals, Inc. retains exclusive rights to these treatments[2].

Key Takeaways

  • Compound Description: The patent covers macrocyclic proline-derived compounds effective against HCV serine protease.
  • Pharmaceutical Compositions: The patent includes claims for various pharmaceutical compositions of these compounds.
  • Methods of Use: The patent covers methods for treating HCV infection using these compounds.
  • Patent Expiration: The patent expires on January 19, 2032.
  • Patent Landscape: The patent is part of a complex landscape of HCV treatment patents, with Enanta Pharmaceuticals, Inc. holding a unique position.

FAQs

Q: Who are the inventors of United States Patent 8,648,037?

A: The inventors are Or Yat Sun, Ma Jun, Wang Guoqiang, Long Jiang, and Wang Bin.

Q: What is the assignee of this patent?

A: The assignee is Enanta Pharmaceuticals, Inc.

Q: What is the primary focus of this patent?

A: The patent focuses on macrocyclic proline-derived compounds that inhibit the HCV serine protease.

Q: When does the patent expire?

A: The patent expires on January 19, 2032.

Q: How does this patent fit into the broader HCV treatment landscape?

A: This patent is part of a complex landscape involving multiple patents from various companies, each with unique approaches to treating HCV.

Cited Sources

  1. United States Patent 8,648,037 - Macrocyclic proline derived HCV serine protease inhibitors[2].
  2. Drugs.com - Generic Mavyret Availability[2].
  3. SLWIP - Patent Analytics[3].

More… ↓

⤷  Subscribe


Drugs Protected by US Patent 8,648,037

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Abbvie MAVYRET glecaprevir; pibrentasvir PELLETS;ORAL 215110-001 Jun 10, 2021 RX Yes Yes ⤷  Subscribe ⤷  Subscribe Y ⤷  Subscribe
Abbvie MAVYRET glecaprevir; pibrentasvir TABLET;ORAL 209394-001 Aug 3, 2017 RX Yes Yes ⤷  Subscribe ⤷  Subscribe Y ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,648,037

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office 2618831 ⤷  Subscribe 300900 Netherlands ⤷  Subscribe
European Patent Office 2618831 ⤷  Subscribe CR 2017 00048 Denmark ⤷  Subscribe
European Patent Office 2618831 ⤷  Subscribe PA2017034 Lithuania ⤷  Subscribe
European Patent Office 2618831 ⤷  Subscribe 122017000076 Germany ⤷  Subscribe
European Patent Office 2618831 ⤷  Subscribe LUC00037 Luxembourg ⤷  Subscribe
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.